AltIndex assigns Hold to Microbot Medical stock at USD 1.06 target

Microbot Medical (ISIN US59503A2042) was assigned a Hold signal with a USD 1.06 six-month target by AltIndex on October 6, 2026. The assessment gives investors a separate valuation reference as the company moves from product development toward commercialization.

AI target signals caution

According to AltIndex on October 6, 2026, the model assigned Microbot Medical a Hold view and a USD 1.06 six-month price target. The same page describes the signal as an AI forecast built from financial, technical and alternative-data inputs rather than a conventional investment-bank research target.

The figure matters because the model's target is presented in U.S. dollars, while the reference quotation for German investors is in euros. That separation prevents the two prices from being treated as one direct daily comparison.

Revenue has started to expand

Microbot Medical reported USD 0.24 million in revenue for the second quarter of 2026, compared with USD 0.13 million in analyst estimates, according to MarketBeat. The same report lists adjusted? No, it lists reported earnings per share of minus USD 0.08 against consensus of minus USD 0.08 for the quarter.

The revenue comparison is the stronger operating signal, but the earnings figure shows that higher sales have not yet translated into a positive result. Microbot Medical develops robotic systems for endovascular procedures, with the LIBERTY system central to its commercialization strategy.

Stock stays near its yearly low

Finance data put Microbot Medical's market capitalization at USD 51.0 million on October 7, 2026, with a 52-week range of USD 1.05 to USD 3.28. The current valuation therefore sits close to the lower end of its annual range, while the AltIndex target remains a separate model estimate rather than company guidance.

MarketWatch identifies MBOT as a Nasdaq-listed security and reported three analyst ratings on its quote page. For investors, the key tension is clear: quarterly revenue is above consensus, but the company remains loss-making and the share price is close to its 52-week low.

Euro quote and daily move

MBOT was trading at EUR 1.00 at Lang & Schwarz on October 8, 2026 at 12:31 p.m. CEST, minus 1.96 percent versus the Lang & Schwarz prior close of EUR 1.02 on October 7, 2026. The quote is intraday and uses the euro reference price for investors in Germany. The further course of trading is shown by the continuously updated real-time quote of Microbot Medical stock.

More news and analyses on Microbot Medical stock